# IHC 1+ and Greater (NCT05911295)

> Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05911295
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Urothelial Carcinoma
- Interventions: disitamab vedotin; pembrolizumab; gemcitabine; cisplatin; carboplatin
- Enrollment: 412
- Primary outcome: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
- Primary outcome: Overall survival (OS)

## Indexed commentary on IHC 1+ and Greater so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ihc-1-and-greater-nct05911295

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05911295", "email": "<work email>"}; the inbox owner confirms by the emailed link.